|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
7 April 2015 |
|
Main ID: |
NCT00004831 |
|
Date of registration:
|
24/02/2000 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
October 1996 |
|
Target sample size:
|
20 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00004831 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
|
Phase:
|
N/A
|
|
|
Contacts
|
|
Name:
|
Micheline M Mathews-Roth |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
St. Luke's-Roosevelt Hospital Center |
| | |
|
Key inclusion & exclusion criteria
|
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Documented erythropoietic protoporphyria Determination of
elevated protoporphyrin within the past year Experiencing photosensitivity
--Prior/Concurrent Therapy-- No concurrent use of betacarotene --Patient Characteristics--
Other: Not pregnant or nursing Fertile female patients must use effective contraception
while on study and for 3 weeks thereafter
Age minimum:
18 Years
Age maximum:
65 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Erythropoietic Protoporphyria
|
|
Intervention(s)
|
|
Drug: cysteine hydrochloride
|
|
Secondary ID(s)
|
|
199/13413
|
|
SLRH-CU-FDR000996-EF
|
|
BWH-FDR000996-EF
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|